Compare NPCE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | ENTA |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.3M | 374.6M |
| IPO Year | 2021 | 2012 |
| Metric | NPCE | ENTA |
|---|---|---|
| Price | $15.48 | $14.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $18.33 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 165.9K | 110.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.03 | ★ 29.93 |
| EPS | N/A | ★ N/A |
| Revenue | $99,986,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $0.90 | $7.76 |
| Revenue Next Year | $24.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.13 | 16.48 |
| 52 Week Low | $7.56 | $4.96 |
| 52 Week High | $18.97 | $17.15 |
| Indicator | NPCE | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 57.22 |
| Support Level | $15.25 | $13.39 |
| Resistance Level | $15.71 | $15.52 |
| Average True Range (ATR) | 0.67 | 0.76 |
| MACD | 0.22 | 0.20 |
| Stochastic Oscillator | 91.26 | 74.84 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.